GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » EV-to-EBITDA

Peptron (XKRX:087010) EV-to-EBITDA : -67.80 (As of Jun. 08, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Peptron EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Peptron's enterprise value is ₩864,698 Mil. Peptron's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-12,754 Mil. Therefore, Peptron's EV-to-EBITDA for today is -67.80.

The historical rank and industry rank for Peptron's EV-to-EBITDA or its related term are showing as below:

XKRX:087010' s EV-to-EBITDA Range Over the Past 10 Years
Min: -445.19   Med: -47.35   Max: -7
Current: -67.79

During the past 10 years, the highest EV-to-EBITDA of Peptron was -7.00. The lowest was -445.19. And the median was -47.35.

XKRX:087010's EV-to-EBITDA is ranked worse than
100% of 450 companies
in the Biotechnology industry
Industry Median: 9.385 vs XKRX:087010: -67.79

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-08), Peptron's stock price is ₩41750.00. Peptron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-775.000. Therefore, Peptron's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Peptron EV-to-EBITDA Historical Data

The historical data trend for Peptron's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron EV-to-EBITDA Chart

Peptron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.96 -19.31 -17.71 -15.39 -65.72

Peptron Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.33 -22.10 -49.79 -65.72 -46.29

Competitive Comparison of Peptron's EV-to-EBITDA

For the Biotechnology subindustry, Peptron's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peptron's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peptron's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Peptron's EV-to-EBITDA falls into.



Peptron EV-to-EBITDA Calculation

Peptron's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=864698.374/-12753.744
=-67.80

Peptron's current Enterprise Value is ₩864,698 Mil.
Peptron's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-12,754 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Peptron  (XKRX:087010) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Peptron's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=41750.00/-775.000
=At Loss

Peptron's share price for today is ₩41750.00.
Peptron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-775.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Peptron EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Peptron's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Peptron (XKRX:087010) Business Description

Traded in Other Exchanges
N/A
Address
37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron (XKRX:087010) Headlines

No Headlines